15 results about "Reduced toxicity" patented technology

This invention provides a non-cytotoxic, in vivo compatible proximity labeling method for peroxidases, Hi-APEX, and its applications, belonging to the field of biotechnology. This invention provides a method for labeling interacting proteins, neighboring proteins, and / or neighboring RNA. By introducing TP probes, it completely overcomes the core limitation of peroxidase dependence on H2O2 without sacrificing the original high spatiotemporal resolution. The method provided by this invention exhibits significantly superior technical effects compared to existing technologies in terms of reduced toxicity, enabling in vivo application, precise analysis of redox-sensitive processes, dynamic tracking of protein transport, and simultaneous spatial multi-omics analysis. It provides a powerful tool for life science research and drug development, possessing significant scientific value and broad application prospects.

A ketorolaco derivative as shown in formula (I) has a better half-life and stability, has good pharmacokinetic properties, and has a higher stability in vitro; and as a preparation, the ketorolaco derivative can enhance efficacy and reduce toxicity. The present invention well improves the defects of frequent administration, gastrointestinal side effects, poor compliance and the like in traditional ketorolaco preparations.

Disclosed is a simplified, readily scalable series of individual methods that collectively constitute a method for the synthesis of C2'epiAmB, an efficacious and reduced-toxicity derivative of amphotericin B (AmB), beginning from AmB. Also provided are various compounds corresponding to intermediates in accordance with the series of methods.

This invention discloses the preparation method and application of lipid prodrugs and self-microemulsion formulations of taxane compounds, belonging to the field of pharmaceutical technology. This invention discloses two lipid prodrugs substituted with long-chain fatty acids at positions 1,3, bridged by disulfide bonds, as shown in the following formula. The aim is to improve the oral absorption efficiency of ralotathol and SB-T-1214, promote their specific release at the target site, and achieve synergistic effects and reduced toxicity. The self-microemulsion drug delivery system is suitable for lipid-soluble drugs and has advantages such as simple preparation process, high drug loading, and easy process scale-up. The prepared self-microemulsion formulation consists of ralotathol or SB-T-1214 lipid prodrugs and excipients. The excipients include an oil phase and an emulsifier. By mass percentage, the oil phase accounts for 40-75% of the self-microemulsion formulation, the emulsifier accounts for 25-60%, and the ralotathol or SB-T-1214 lipid prodrug accounts for 1-10% of the total mass of the excipients.

This invention relates to an immunotoxin targeting hematologic malignancies and its application. The immunotoxin comprises a toxic molecule and a carrier. The toxic molecule is pumpkin protein or a mutant of pumpkin protein. The carrier contains an antibody, ligand, or polypeptide capable of binding to hematologic malignancies cells. The antibody comprises an antibody fragment or a small molecule antibody. This invention provides an immunotoxin targeting hematologic malignancies for the treatment of these malignancies. The immunotoxin using a pumpkin protein mutant as the toxic molecule exhibits enhanced specificity against hematologic malignancies cells with high target expression, significantly increased activity in killing target cells, and allows for a substantial reduction in dosage and toxicity. In summary, the immunotoxin targeting hematologic malignancies using a pumpkin protein mutant as the toxic molecule offers advantages in both synergistic effect and reduced toxicity, and has broad application prospects.

The present invention relates to a method for producing 1B or 1D omega-5 gliadin-deleted wheat and wheat produced thereby, and, specifically, to a method for producing and selecting 1B or 1D omega-5 gliadin gene-deleted wheat by using radiation. The method for producing 1B or 1D omega-5 gliadin-deleted wheat, according to the present invention, enables the production of a radiation breeding-based non-GMO mutant wheat or wheat breeding parental line while retaining agronomic traits similar to those of a wild-type wheat variety, and thus wheat with reduced toxicity to wheat-dependent exercise-induced anaphylaxis (WDEIA) can be produced for use in the production of processed wheat foods and the like, or a parental line for breeding wheat varieties with reduced toxicity to WDEIA can be produced.

The application discloses a sulfur-containing compound with active amino groups and a preparation method and application thereof. The compound has the following structural formula. The compound can be used as a hydrogen sulfide donor, can generate a fluorophore while releasing and delivering H2S, can monitor the process of H2S release in vitro and in vivo in real time, can monitor H2S release in a complex biological system in situ and in real time, can visualize and quantify the released H2S, can exert the biological activity of the H2S, and can reduce the toxicity.

Disclosed are multispecific antibodies comprising an antibody or antigen binding fragment targeting CD3, an antibody or antigen binding fragment targeting 4-1BB, and another antibody or antigen binding fragment specific for a tumor associated antigen, such as WT1 presented by HLA-A2, expressed in a variety of tumor cancers. Such multispecific antibodies have enhanced efficacy and reduced toxicity, and are thus particularly suitable for treating diseases such as cancer.

This invention provides gold nanoparticles and their preparation method, comprising the following components by mass percentage: chloroauric acid 5-5%, quercetin 1-3%, chitosan 0.5-2%, hexadecyltrimethylammonium bromide 0.1-0.5%, and ultrapure water 92-93%; wherein the degree of deacetylation of chitosan is ≥90%. This invention uses natural quercetin instead of sodium borohydride as a reducing agent, reducing toxic byproducts and conforming to green chemistry principles; by using chitosan (degree of deacetylation ≥90%) as a stabilizer, it imparts positive charge properties to the particles, enhancing cellular uptake efficiency and reducing toxicity.

This invention belongs to the field of food processing technology and discloses a vinegar-egg beverage with lipid-lowering effects and its production method. The beverage comprises, by weight, 25-30 parts vinegar-egg enzymatic hydrolysate, 1.2-1.5 parts fermented extract of traditional Chinese medicine, 2.0-3.0 parts hawthorn juice, 6.0-6.5 parts jujube extract, and 0.05-0.1 parts sodium alginate. The vinegar-egg liquid of this invention undergoes enzymatic hydrolysis using multiple enzymes. Utilizing the complementarity of different enzymes, a better hydrolysis effect than using a single enzyme is achieved. Kudzu root, Poria cocos, Astragalus membranaceus, and Polygonatum sibiricum are fermented using a compound microbial strain. Through the powerful enzyme system and metabolic capacity of microorganisms, the inherent components of the traditional Chinese medicine are thoroughly released, achieving the purpose of synergistic effect and reduced toxicity. This vinegar-egg beverage helps maintain the health of people with high blood lipids, providing an efficient and stable solution for them, and has significant scientific value and broad market prospects.

The present invention relates to a PVC / CPVC solvent cement formulations using less toxic ketonic solvent mixtures comprising of first three members in homologous series of ketones having one low boiling ketone with boiling point less than 70°C and solvent mixture having two medium boiling ketones with boiling point around 100°C. The solvent cement formulation disclosed in the present invention is less toxic, low VOC and fast curing method of preparing said composition comprising PVC / CPVC solvent cement, which is less toxic, low VOC, fast curing and cost effective.

The present invention provides designed oligonucleotides, compositions, and methods thereof (e.g., altering transcriptional splicing, lower toxicity, providing an improved protein binding profile, improved delivery, improved uptake, etc.). [Solution] A chiral-controlled oligonucleotide composition comprising a plurality of oligonucleotides of a specific oligonucleotide type defined by (1) base sequence; (2) crosslinking pattern of the skeleton; (3) chiral center pattern of the skeleton; and (4) phosphorus modification pattern of the skeleton.

The present invention provides novel small-molecule compounds with tumor necrosis factor-alpha (TNF-α) and interleukin-17 (IL-17) inhibitory properties, intended for oral administration in the treatment of inflammatory and autoimmune diseases, such as psoriasis and rheumatoid arthritis. These compounds selectively inhibit TNF-α and IL-17, key cytokines implicated in chronic inflammation and immune dysregulation. The compounds of this invention overcome these limitations by offering an orally administrable, cost-effective alternative with high specificity and reduced toxicity. The synthetic methods for preparing the compounds, as well as pharmaceutical formulations are also disclosed.

Treatment combinations are provided for FOLR1-binding immunoconjugates (e.g., IMGN853) with anti-VEGF agents (e.g., bevacizumab), platinum-based agents, and / or doxorubicin. Methods for administering said combinations to treat cancers, such as ovarian cancer, with increased clinical efficacy and / or reduced toxicity are also provided.

The present invention relates to a method for producing 33-mer alpha-gliadin-deleted wheat and wheat produced thereby and, specifically, to a method for producing α-D4-1 and α-D4-2 genes-deleted wheat by using radiation and selecting same. The method for producing 33-mer alpha-gliadin-deleted wheat, according to the present invention, enables the production of a mutant wheat or wheat breeding parental line, which is a radiation breeding-based non-GMO, while having agronomic traits similar to those of a wild-type wheat variety, and thus wheat with reduced toxicity to celiac disease can be produced, for use in the production of processed wheat foods and the like, or a parental line for wheat breeding varieties with reduced toxicity to celiac disease can be produced.